Desflurane vs. Propofol for Cardiac Anesthesia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

3560 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-20

Study Completion Date

2029-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate whether the inhaled anesthetic desflurane, compared with propofol, exerts cardioprotective effects and reduces the incidence of severe postoperative major cardiac events in patients undergoing coronary artery bypass graft (CABG) surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Desflurane Versus Propofol Anesthesia for Off-Pump CABG

NCT00528515

Coronary Artery Disease

COMPLETED PHASE4

Anesthesia and Lymphocytes Apoptosis

NCT01461551

Anesthesia

COMPLETED NA

Comparison Between Propofol and Inhalational Anaesthetic Agents on Cardiovascular Outcomes Following Cardiac Surgery

NCT04039854

Coronary Heart Disease Cardiovascular Diseases

UNKNOWN PHASE4

Propofol Cardioprotection for Type II Diabetics

NCT00734383

Myocardial Injury

COMPLETED PHASE2/PHASE3

Compare Hemodynamic Parameters of Propofol and Sevoflurane During CPB Time in Undergoing CABG to Avoid Lactate Level

NCT05004545

Hemodynamic Instability

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cardiac surgery is among the highest-risk surgical procedures, with a high incidence of severe postoperative complications that affect patient prognosis. It is a critical factor significantly increasing perioperative mortality and poses a major challenge to the prognosis of patients undergoing cardiac surgery. Coronary-artery bypass grafting (CABG) is the most common cardiac surgery, with over 300,000 procedures performed annually in the United States alone. The incidence of cardiac complications after cardiac surgery is as high as 50%, including approximately 35% for new-onset atrial fibrillation, 30% for acute kidney injury, 16% for respiratory failure, 5% for severe infection, and an in-hospital mortality rate of about 3.5%. Key pathogenic factors contributing to severe complications after cardiac surgery include surgical stress responses, insufficient organ perfusion during perioperative management, and tissue/organ damage or dysfunction caused by oxidative stress responses induced by the release of inflammatory factors.

Outcomes and prognosis following cardiac surgery are influenced by patient characteristics, surgical techniques, and perioperative management. Over the years, we have continuously sought to develop effective strategies to reduce the incidence of perioperative complications and mortality. Anesthesia for CABG (Coronary Artery Bypass Graft) is typically induced solely with intravenous agents (Total Intravenous Anesthesia - TIVA) or using a combination of volatile (inhaled) and intravenous agents. When administered prior to, during, or after an ischemic event, volatile anesthetics exert cytoprotective effects via multiple mechanisms. These include modulating G protein-coupled receptors, intracellular signaling pathways, gene expression, potassium channels, and mitochondrial function . Furthermore, volatile anesthetics reduce myocardial infarct size in animal models. Several randomized controlled trials (RCTs) suggest volatile anesthetics can reduce biomarkers of myocardial injury, even when administered for only a brief period before ischemia. Additionally, inhaled anesthetics , besides reducing postoperative cardiac troponin release and preserving cardiac function after cardiac surgery, may also lower the risk of myocardial infarction .

However, the impact of volatile anesthetics on postoperative complications and mortality following cardiac surgery remains inconsistent. Some meta-analyses have demonstrated reduced mortality after CABG with volatile anesthetics, a finding consistent with observations from moderate-sized randomized controlled trials. Two international consensus conferences identified volatile anesthetics as key non-surgical interventions to improve survival in patients undergoing major surgery, with potential significant clinical implications for over 300 million surgical patients annually. Guidelines from the American College of Cardiology, American Heart Association, and European Association for Cardio-Thoracic Surgery recommend applying these findings to anesthetic management in cardiac surgery patients, advocating inhalational anesthetics for maintenance in patients at cardiovascular risk to reduce postoperative complications. However, other randomized controlled trials and meta-analyses have failed to confirm such benefits. Conflicting results also exist regarding postoperative complications, including pulmonary complications, neurocognitive disorders, and renal injury.

The large-scale international multicenter Myriad trial-designed to enroll 10,600 patients undergoing isolated CABG to compare inhalational anesthetics (isoflurane, sevoflurane, or desflurane) versus intravenous propofol on postoperative mortality-the study was prematurely terminated for futility after enrolling 5,400 CABG cases. Interim analysis revealed no differences in 30-day and 1-year all-cause mortality between volatile anesthesia and total intravenous anesthesia (TIVA) groups. Another multicenter study (Br J Anaesth. 2024 Aug;133(2):296-304), involving 3,123 cardiac surgery patients across 16 Chinese centers, compared inhalational (sevoflurane/desflurane) and intravenous (propofol) anesthesia for composite outcomes including 30-day all-cause mortality and severe organ complications. No significant difference was observed: 33.8% in the inhalational group versus 33.2% in the intravenous group (adjusted OR 1.05, 95% CI 0.90-1.22; P=0.57).

Desflurane , introduced into clinical practice in 1990 as an inhaled anesthetic, is characterized by rapid induction and recovery , contributing to reduced postoperative recovery-related complications . Studies confirm that desflurane anesthesia lowers the surgical stress response , aiding in the maintenance of hemodynamic stability . Furthermore, multiple studies have found that compared to intravenous anesthesia, desflurane offers superior myocardial protection for CABG patients, reducing pulmonary complications, shortening hospital stays, lowering mortality, and improving quality of life . Its mechanisms may relate to its effects on mitochondrial permeability transition pore, mitochondrial electron transport chain, reactive oxygen species, ATP-sensitive potassium channels, G protein-coupled receptors, and protein kinase C biological functions. In non-cardiac surgery, desflurane did not reduce postoperative respiratory complications compared to sevoflurane . Although clinical evidence supporting the beneficial effects of inhaled anesthetics, particularly desflurane, in cardiac surgery patients is limited and insufficient , they do highlight its potential advantages . Research into desflurane's optimal administration method and dosage , as well as its long-term effects , is ongoing.

A recently published Meta-analysis indicated that, compared to propofol , desflurane demonstrated potential clinical benefit for surgical patients in terms of 30-day mortality, incidence of myocardial infarction, new-onset postoperative atrial fibrillation, postoperative pneumonia, and atelectasis . However, these findings stemmed from small sample sizes and underpowered studies .

Based on the available evidence, the inconsistent conclusions across current studies may stem from :

1. Differential organ-specific effects of inhalational versus intravenous anesthetics: Inhalational agents confer significant cardiovascular benefits, whereas intravenous agents offer neurological advantages. Consequently, using mortality or composite outcomes encompassing severe complications across all organ systems as primary endpoints leads to confounding of divergent effects, posing challenges for result interpretation and clinical practice guidance.
2. Heterogeneity in cardioprotective efficacy among inhalational agents: Existing studies have not restricted the type of inhalational anesthetics used. When compared to the intravenous agent propofol, commonly used inhalational anesthetics (isoflurane, desflurane, sevoflurane) exhibit heterogeneous cardioprotective effects: isoflurane shows weaker cardioprotection than propofol; sevoflurane demonstrates no significant difference; and desflurane exhibits stronger cardioprotection than propofol.
3. Impact of timing and duration of inhalational anesthetic administration: In clinical practice, the timing and duration of inhalational agent use influence their cardioprotective efficacy, representing a key source of effect heterogeneity across studies.

To date, no study has provided robust evidence supporting a preferred anesthesia regimen or agent for preventing severe complications and reducing mortality after cardiac surgery. Building upon the potential advantages of desflurane in myocardial protection and improving postoperative survival , identified in preliminary small-scale studies or exploratory analyses of other large trials , we plan to initiate a large-scale, national, multi-center randomized clinical trial (DECIDE-CABG trial) .

This trial will enroll 3,560 elective patients undergoing isolated CABG to compare the impact of desflurane-based inhaled anesthesia maintenance versus propofol-based TIVA maintenance on the incidence of major adverse cardiovascular events (MACE) and all-cause mortality at 30 days postoperatively . Through this large-scale, multi-center, randomized controlled study , we aim to definitively identify the optimal anesthesia regimen and anesthetic agents for CABG patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Surgery Coronary Artery Bypass Grafting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Desflurane group

After routine induction, anesthesia is maintained with inhaled desflurane, with the concentration adjusted as needed to maintain 0.5-2 MAC .Propofol is not used to maintain anesthesia during the whole anesthesia maintenance process, except during cardiopulmonary bypass.

Group Type EXPERIMENTAL

Desﬂurane group

Intervention Type DRUG

After routine induction, maintain anesthesia with inhaled desflurane , adjusting concentration as needed to sustain 0.5-2 MAC . To maximize the cardioprotective effects of inhaled anesthetics, adhere to this intraoperative strategy:

Maintain ≥1 MAC continuous desflurane for ≥30 minutes ; For on-pump CABG , discontinue desflurane 15 minutes before initiating cardiopulmonary bypass (CPB) ;

If intraoperative desflurane cessation is required, implement a wash-in/wash-out strategy (recommended but non-mandatory):

Perform 3 alternating cycles of:

Wash-in : ≥10 minutes of desflurane at ≥0.5 MAC, Wash-out : ≥10 minutes of complete cessation of inhaled anesthetics. Propofol is strictly prohibited for anesthesia maintenance throughout the procedure , except during CPB.

Propofol group

3-8 mg/kg/h intravenous infusion of propofol to implement total intravenous anesthesia maintenance, without the use of any inhaled anesthetic drugs, can be maintained by intravenous targeted infusion or manual adjustment of intravenous infusion.

Group Type ACTIVE_COMPARATOR

Propofol group

1. Emergency or urgent operation
2. Concomitant valve or aortic surgery
3. History of myocardial infarction in recent 30 days
4. Current use of myocardial preconditioning-affecting medications, such as sulfonylurea (glibenclamide), allopurinol, theophylline, nicorandil(last dose \< 8 hrs), etc
5. Participated in other randomized controlled clinical trials in recent 3 months
6. General anesthesia in recent 30 days
7. History of kidney and liver transplantation, or severe liver and kidney dysfunction (EGFR ≤ 20 mlgmin/1.73 m2, conventional dialysis or patients who have started dialysis; Child Pugh grade C/cirrhosis)
8. History of open heart surgery;
9. Hemodynamic instability or severe heart failure (SBP\<90 mmHg or preoperative need of high-dose vasoactive drug support, placement of aortic balloon pump (IABP), ECMO or ventricular assist device, left ventricular ejection fraction\<30%)
10. Adverse drug reactions to trial medications
11. History of malignant hyperthermia
12. Pregnancy or lactation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No